Pfizer Inc. Earnings: Can They Grow Without AstraZeneca?

Pfizer is making a big push to buy AstraZeneca, but is that the only growth strategy for Pfizer going forward?

May 2, 2014 at 2:30PM

On Monday, Pfizer (NYSE:PFE) will release its quarterly report, and despite strong markets over the past year, the pharmaceutical giant's shares have stayed in a tight range. Investors are pondering how Pfizer can best foster growth in an increasingly competitive industry, and Pfizer's aggressive pursuit of AstraZeneca (NYSE:AZN) seems like an obvious way to get it. But does Pfizer really need AstraZeneca in order to keep pace with Merck (NYSE:MRK) and its other rivals?

Pfizer has faced the same patent-cliff woes that Merck and other major pharma companies have dealt with in recent years, with Pfizer's blockbuster drug Lipitor having lost patent protection and led to a big drop in revenue and net income. Even though Pfizer has new drugs like Lyrica and Enbrel to help restore that lost revenue, newer offerings like Eliquis and Xeljanz haven't had the strong starts that investors had hoped to see. With investors less excited about Pfizer's pipeline prospects than Merck's and those of other peers, Pfizer's potential buyout of AstraZeneca would give the company a bigger presence in the cancer-treatment space. Let's take an early look at what's been happening with Pfizer over the past quarter and what we're likely to see in its report.

Pfe

Stats on Pfizer

Analyst EPS Estimate

$0.55

Change From Year-Ago EPS

7.8%

Revenue Estimate

$12.07 billion

Change From Year-Ago Revenue

(10.6%)

Earnings Beats in Past 4 Quarters

3

Source: Yahoo! Finance

Can Pfizer earnings keep clawing back lost ground?
In recent months, analysts have been a bit downbeat on Pfizer earnings, cutting full-year 2014 and 2015 projections by 1% to 3%. The stock has posted modest gains, rising 3% since late January.

Pfizer's fourth-quarter results gave investors hope that the pharma giant could stand up to Merck and its other rivals. Revenue dropped 2% from the year-ago quarter, but that entire decline was due to adverse currency impacts, with sales having climbed 1% on a constant-currency basis. Similarly, Pfizer's roughly 60% drop in earnings was due to the sale of its nutritional-products division last year, and adjusted earnings climbed nicely from year-ago levels. Sales of Lyrica gained 11%, and Enbrel provided a 5% gain in sales to help keep Pfizer's overall revenue higher.

But the long-term health of Pfizer's business relies on its pipeline, and results from clinical trials during the quarter have been both good and bad. Lung-cancer drug dacomitinib failed to meet its primary goals in late-stage trials, demonstrating a lack of statistically significant survival compared both against a competing treatment and to a placebo. Yet breast-cancer drug palbociclib showed promise in a phase 2 study, and many believe that Pfizer could skip phase 3 trials entirely and seek FDA approval based solely on the completed trial's data. In addition, Pfizer's vaccine business has produced steady growth, with its Prevnar series taking advantage of the competitive moat that prevents most generic-drug producers from tackling the job of copying vaccines.

Still, Pfizer wants even more growth, and that's a big impetus for its pursuit of AstraZeneca. Pfizer has justified its initial bid of more than $100 billion for AstraZeneca by arguing that combining the two companies' cancer-treatment development areas could create new opportunities, especially in immuno-oncology. Yet there are also other areas where the two companies would complement each other well, with AstraZeneca filling in gaps in Pfizer's coverage in the cardiovascular realm. Moreover, the promise of being able to move its headquarters across the Atlantic could produce substantial tax savings, further boosting earnings. This morning, AstraZeneca rejected Pfizer's latest bid of roughly $106 billion, arguing that even the 7% boost from the initial bid was still inadequate given the large percentage of Pfizer stock involved and AstraZeneca's desire to remain independent.

In the Pfizer earnings report, look at the numbers that the pharma giant delivers on the sales and earnings fronts. But also listen for clues about how those numbers will change if an AstraZeneca merger goes through. With AstraZeneca having resisted initial attempts at a combination, Pfizer will have to persuade shareholders that the acquisition is the smartest way for it to stand up to Merck and keep growing. Pfizer can grow without AstraZeneca, but a big merger could be a much easier way to find growth for Pfizer.

Top dividend stocks for the next decade
The smartest investors know that dividend stocks simply crush their non-dividend paying counterparts over the long term. That’s beyond dispute. They also know that a well-constructed dividend portfolio creates wealth steadily, while still allowing you to sleep like a baby. Knowing how valuable such a portfolio might be, our top analysts put together a report on a group of high-yielding stocks that should be in any income investor’s portfolio. To see our free report on these stocks, just click here now.

Click here to add Pfizer to My Watchlist, which can find all of our Foolish analysis on it and all your other stocks.

Dan Caplinger has no position in any stocks mentioned. The Motley Fool has no position in any of the stocks mentioned. Try any of our Foolish newsletter services free for 30 days. We Fools may not all hold the same opinions, but we all believe that considering a diverse range of insights makes us better investors. The Motley Fool has a disclosure policy.

1 Key Step to Get Rich

Our mission at The Motley Fool is to help the world invest better. Whether that’s helping people overcome their fear of stocks all the way to offering clear and successful guidance on complicated-sounding options trades, we can help.

Feb 1, 2016 at 4:54PM

To be perfectly clear, this is not a get-rich action that my Foolish colleagues and I came up with. But we wouldn't argue with the approach.

A 2015 Business Insider article titled, "11 websites to bookmark if you want to get rich" rated The Motley Fool as the #1 place online to get smarter about investing.

"The Motley Fool aims to build a strong investment community, which it does by providing a variety of resources: the website, books, a newspaper column, a radio [show], and [newsletters]," wrote (the clearly insightful and talented) money reporter Kathleen Elkins. "This site has something for every type of investor, from basic lessons for beginners to investing commentary on mutual funds, stock sectors, and value for the more advanced."

Our mission at The Motley Fool is to help the world invest better, so it's nice to receive that kind of recognition. It lets us know we're doing our job.

Whether that's helping the entirely uninitiated overcome their fear of stocks all the way to offering clear and successful guidance on complicated-sounding options trades, we want to provide our readers with a boost to the next step on their journey to financial independence.

Articles and beyond

As Business Insider wrote, there are a number of resources available from the Fool for investors of all levels and styles.

In addition to the dozens of free articles we publish every day on our website, I want to highlight two must-see spots in your tour of fool.com.

For the beginning investor

Investing can seem like a Big Deal to those who have yet to buy their first stock. Many investment professionals try to infuse the conversation with jargon in order to deter individual investors from tackling it on their own (and to justify their often sky-high fees).

But the individual investor can beat the market. The real secret to investing is that it doesn't take tons of money, endless hours, or super-secret formulas that only experts possess.

That's why we created a best-selling guide that walks investors-to-be through everything they need to know to get started. And because we're so dedicated to our mission, we've made that available for free.

If you're just starting out (or want to help out someone who is), go to www.fool.com/beginners, drop in your email address, and you'll be able to instantly access the quick-read guide ... for free.

For the listener

Whether it's on the stationary exercise bike or during my daily commute, I spend a lot of time going nowhere. But I've found a way to make that time benefit me.

The Motley Fool offers five podcasts that I refer to as "binge-worthy financial information."

Motley Fool Money features a team of our analysts discussing the week's top business and investing stories, interviews, and an inside look at the stocks on our radar. It's also featured on several dozen radio stations across the country.

The hosts of Motley Fool Answers challenge the conventional wisdom on life's biggest financial issues to reveal what you really need to know to make smart money moves.

David Gardner, co-founder of The Motley Fool, is among the most respected and trusted sources on investing. And he's the host of Rule Breaker Investing, in which he shares his insights into today's most innovative and disruptive companies ... and how to profit from them.

Market Foolery is our daily look at stocks in the news, as well as the top business and investing stories.

And Industry Focus offers a deeper dive into a specific industry and the stories making headlines. Healthcare, technology, energy, consumer goods, and other industries take turns in the spotlight.

They're all informative, entertaining, and eminently listenable ... and I don't say that simply because the hosts all sit within a Nerf-gun shot of my desk. Rule Breaker Investing and Answers contain timeless advice, so you might want to go back to the beginning with those. The other three take their cues from the market, so you'll want to listen to the most recent first. All are available at www.fool.com/podcasts.

But wait, there's more

The book and the podcasts – both free ... both awesome – also come with an ongoing benefit. If you download the book, or if you enter your email address in the magical box at the podcasts page, you'll get ongoing market coverage sent straight to your inbox.

Investor Insights is valuable and enjoyable coverage of everything from macroeconomic events to investing strategies to our analyst's travels around the world to find the next big thing. Also free.

Get the book. Listen to a podcast. Sign up for Investor Insights. I'm not saying that any of those things will make you rich ... but Business Insider seems to think so.


Compare Brokers